VRAX
VRAX
NASDAQ · Health Care

Virax Biolabs Group Ltd

$0.14
+0.00 (+0.79%)
As of May 16, 2:37 AM ET ·
Financial Highlights (FY 2026)
Revenue
33.6K
Net Income
-32,119,451
Gross Margin
-838.4%
Profit Margin
-95,754.3%
Rev Growth
D/E Ratio
0.07
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin -838.4% 64.6% 64.6% 64.6%
Operating Margin -97,360.2% 18.7% 17.5% 18.8%
Profit Margin -95,754.3% 14.5% 12.3% 15.6%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 33.6K 514.8K 538.6K 459.7K
Gross Profit -281,749 332.5K 347.9K 296.9K
Operating Income -32,718,865 96.5K 94.4K 86.3K
Net Income -32,119,451 74.6K 66.4K 71.8K
Gross Margin -838.4% 64.6% 64.6% 64.6%
Operating Margin -97,360.2% 18.7% 17.5% 18.8%
Profit Margin -95,754.3% 14.5% 12.3% 15.6%
Rev Growth +21.9% -4.1% +16.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 86.6K 378.4K 385.3K 374.1K
Total Equity 1.31M 1.00M 916.7K 903.3K
D/E Ratio 0.07 0.38 0.42 0.41
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -30,747,535 106.1K 122.1K 91.8K
Free Cash Flow 64.8K 82.7K 52.1K